多西紫杉醇联合顺铂治疗晚期非小细胞肺癌32例被引量：1

导出

摘要目的观察多西紫杉醇联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法收集可评价疗效的晚期 NSCLC 患者32例,多西紫杉醇75mg/m^2静脉滴注,第1天;顺铂20～30mg/m^2静脉滴注,第2天至第5天,每3周为1个周期,2～3周期后评价疗效。结果 32例患者中,总有效率为50.0%,其中初治病例为54.5%,复治病例为40.0%,两者差异无统计学意义(P>0.05)。中位缓解期为5个月。中位生存期为9.5个月。不良反应主要为骨髓抑制,白细胞下降达Ⅲ、Ⅳ度者40.6%,血小板下降达Ⅲ、Ⅳ度者为12.5%。血红蛋白下降不严重。消化道反应达Ⅲ、Ⅳ度者占15.6%,变态反应、脱发、水钠潴留、静脉炎、末梢神经炎、口腔炎、腹泻等发生率均较低。结论多西紫杉醇联合顺铂治疗晚期 NSCLC疗效满意,特别对复发病例能明显改善生存率。经适当的预处理,患者严重的不良反应发生较低。

作者白丽姚玉华赵瑞红

机构地区山西中医学院中西医结合医院呼吸内科

出处《肿瘤研究与临床》 CAS 2007年第12期835-836,共2页 Cancer Research and Clinic

关键词癌非小细胞肺抗肿瘤联合化疗方案

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1易青,汪安兰,周辉.多西他赛联合顺铂或卡铂治疗老年晚期非小细胞肺癌的比较研究[J].中华肿瘤防治杂志,2006,13(11):879-879. 被引量：1
2李峻岭,张湘茹,刘基巍,陈中元,林英城,王远东,陈强,南克俊,宋恕平,韩福才,朱允中,李龙芸,郑玉红,储大同.泰索帝每周给药联合顺铂一线治疗晚期非小细胞肺癌的临床研究[J].中华肿瘤杂志,2006,28(4):309-312. 被引量：24
3任振义,白春学,金一尊,洪群英,曾昭冲.多烯紫杉醇对非小细胞肺癌的抑制作用及其机制[J].中华结核和呼吸杂志,2003,26(2):127-127. 被引量：3
4Y. H. Kim,J. S. Kim,Y. H. Choi,K. H. In,H. S. Park,D. S. Hong,T. J. Jeong,Y. Y. Lee,E. Nam,S. N. Lee,K. S. Lee,H. K. Kim.Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. International Journal of Clinical Oncology . 2002 (2)
5Kim YH,Kim JS,Choi YH,et al.PhaseⅡstudy of docetaxeland cisplatin combination chemotherapy in metastatic or unresect-able localized non-small cell lung cancer. International Journal of Clinical Oncology . 2002
6Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. The New England Journal of Medicine . 2002

二级参考文献17

1Francis PA, Rigas JR, Kris MG, et al. Phase Ⅱ trial of docetaxel in patients in with stage Ⅲ and Ⅳ non-small cell lung cancer. J Clin Oncol,1994, 12: 1232-1237.
2Hainsworth JD,Burris Ⅲ HA, Greco FA. Weekly Administration of　Docetaxel (Taxotere): summary of clinical data. Semin Oncol,1999,26( Suppl 10) : 19-24.
3Fossella FV, Lee JS, Murphy WK, et al. Phase Ⅱ study of docetaxel for recurrent or metastatic non small cell lung cancer. J Clin 0ncol, 1994, 12: 1238-1244.
4Fossella FV, Lee JS, Berilh J, et al. Summary of phase Ⅱ data of docetaxel(Taxotere), an active agent in the first and second line treatment of advanced non small cell lung cancer. Semin Oneol,1995, 22(2 Suppl 4) :22-29.
5Belani CP. Single agents in the second line treatment of non small cell lung cancer. Semin 0neol,1998, 25(3 Suppl 8) : 10-14.
6Ravdin PM, Bun'is HA, Cook G, et al. Phase Ⅱ trial of docetaxel inadvanced anthracicline-resistant or anthracenedione-resistant breast cancer. J Clin 0ncol,1995, 13:2879-2885.
7Kubota K, Watanabe K, Kunitoh H,et al. Phase Ⅲ randomized trial of decetaxel plus cisplatin versus vindesine plus cispaltin in patients with stage Ⅳ non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol, 2004, 22:354-261.
8Fossella F, Pereira JR, von Pawel JV, et al. Bandomezed,multinational, phase Ⅲ study of decetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non small cell lungcancer: the TAX 326 study group. J Clin Oncol,2003,21:3016-3024.
9Koizumi T, Tsunoda T, Fujimoto K, et al. Phase Ⅰ trial of weekly docetaxel combined with cisplatin in patients with non small cell lung cancer. Lung Cancer, 2001, 34 : 125-131.
10Ohe Y, Niho S, Kakinuma B, et al. Phase I trial of cisplafin and docetaxel administered by three consecutive weekly infusion for advanced non small cell lung cancer in elderly and non elderly patients. Jpn J Clin Oncol, 2001, 31 : 100-106.